Avandia Market Falls on Safety Concerns
The U.S. market value of GlaxoSmithKline's drug Avandia continues to fall after a report linked the drug to higher rates of heart attacks. Avandia is one of the company's biggest sellers. It is a type of diabetes drug in the thiazolidinedione (TZD) class of drugs.
The recent study was done by Steven Nissen, the head of cardiology at the Cleveland Clinic. It looked at data from 42 trials involving 28,000 patients. Prior to the report, Avandia and Avandament, another GlaxoKlineSmith drug similar to Avandia, had a 53.8 percent share of weekly new drug prescriptions.
Related Links:
Legal View: Avandia
Glaxo's Avandia Dips Anew After Safety Concerns
FDA Has Requested Black Box Warnings For Two Diabetes Medications, Agency Commissioner Says At House Committee Hearing
FDA Scrutinized by Lawmakers ofer Avandia Issues